Promises and challenges of a decentralized CAR T-cell manufacturing model
Open accessAbstract
Autologous chimeric antigen receptor-modified T-cell (CAR T) products have demonstrated un-precedent efficacy in treating many relapsed/refractory B-cell and plasma cell malignancies, leading to multiple commercial products now in routine clinical use. These positive responses to CAR T therapy have spurred biotech and big pharma companies to evaluate innovative production methods to increase patient access while maintaining adequate quality control and profitability. Autologous cellular therapies are, by definition, manufactured as single patient batches, and demand has soared for manufacturing facilities compliant with current Good Manufacturing Practice (cGMP) regulations. The use of a centralized production model is straining finite resources even in developed countries in North America and the European Union, and patient access is not feasible for most of the developing world. The idea of having a more uniform availability of these cell therapy products promoted the concept of point-of-care (POC) manufacturing or decentralized in-house production. While this strategy can potentially decrease the cost of manufacturing, the challenge comes in maintaining the same quality as currently available centrally manufactured products due to the lack of standardized manufacturing techniques amongst institutions. However, academic medical institutions and biotech companies alike have forged ahead innovating and adopting new technologies to launch clinical trials of CAR T products produced exclusively in-house. Here we discuss POC production of CAR T products.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Access to industry-driven CAR-T cell therapy is limited in developing countries, including Thailand, mainly due to the extremely high cost of laborious CAR-T manufacturing in a centralized system and complex logistics.
“However, access to industry-driven CAR-T cell therapy is limited in developing countries, including Thailand, mainly due to the extremely high cost of laborious CAR-T manufacturing to create an autologous product in a centralized system and complex logistics.1,2”
From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [2]
The Abstract says centralized production strains resources and makes access infeasible for most of the developing world. The Limitations section describes prohibitive commercial costs and shipment-related delays, supporting the claim’s general explanation. Our copy does not identify Thailand specifically, so it does not establish the claim about access there. (LLM, conf=0.88)
Experimental — accuracy not yet measuredCentralized manufacturing facilities typically maintain dedicated QA departments and well-established SOPs, whereas decentralized POC sites may lack extensive experience implementing full GMP-compliant QA systems, increasing the risk of inconsistent product quality or regulatory non-compliance.
“Centralized manufacturing facilities typically maintain dedicated QA departments and well-established SOPs, whereas decentralized POC sites may lack extensive experience implementing full GMP-compliant QA systems, increasing the risk of inconsistent product quality or regulatory non-compliance (Shah et al., 2023).”
From Isolator-based point-of-care manufacturing: a practical solution for GMP-compliant cell and extracellular vesicles therapy production (2025) · cites this paper as Shah et al., 2023
Split into 2 atoms — 1 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
Experimental — accuracy not yet measuredDevelopment of bioreactors and closed system manufacturing platforms mitigates the need for expensive infrastructure and simplifies the multistep CAR-T manufacturing process.
“A paradigm shift enabling POC manufacturing is the development of bioreactors and closed system manufacturing platforms that mitigate the need for expensive infrastructure and simplify the multistep process.2,8,9”
From Point-of-care manufacturing of anti-CD19 CAR-T cells using a closed production platform: Experiences of an academic in Thailand (2024) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413 · see citing works
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112 · see citing works
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565 · see citing works
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560 · see citing works
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430 · see citing works
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · see citing works
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862 · see citing works
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756 · cited 1× · see citing works
“An example is provided by Nanjing Biolegend with its anti-BCMA CAR T cell for multiple myeloma, now approved by FDA and promising data from early phase clinical trials with anti-claudin CAR T cells in gastrointestinal malignancies (4, 18, 71).”
MethodAxicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607 · see citing works
Kochenderfer, J. N., Dudley, M. E., Feldman, S. A., Wilson, W. H., Spaner, D., Marić, I., Stetler‐Stevenson, M., Phan, G. Q., Hughes, M. S., Sherry, R. M., et al. (2011) · Blood · doi:10.1182/blood-2011-10-384388 · Cited by 1,441 · see citing works
Kochenderfer, J. N., Wilson, W. H., Janik, J. E., Dudley, M. E., Stetler-Stevenson, M., Feldman, S. A., Maric, I., Raffeld, M., Nathan, D.-A. N., Lanier, B. J., et al. (2010) · Blood · doi:10.1182/blood-2010-04-281931 · Cited by 1,337 · see citing works
Brentjens, R. J., Rivière, I., Park, J. H., Davila, M. L., Wang, X., Stefanski, J., Taylor, C., Yeh, R., Bartido, S. M., Bórquez-Ojeda, O., et al. (2011) · Blood · doi:10.1182/blood-2011-04-348540 · Cited by 1,287 · see citing works
‘Off-the-shelf’ allogeneic CAR T cells: development and challenges
Depil, S., Duchateau, P. N., Grupp, S. A., Mufti, G. J., & Poirot, L. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0051-2 · Cited by 1,238 · see citing works
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
Mackensen, A., Müller, F., Mougiakakos, D., Boeltz, S., Wilhelm, A., Aigner, M., Völkl, S., Simón, D., Kleyer, A., Munoz, L. E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02017-5 · Cited by 1,138 · see citing works
Sommermeyer, D., Hudecek, M., Kosasih, P. L., Gogishvili, T., Maloney, D. G., Turtle, C. J., & Riddell, S. R. (2015) · Leukemia · doi:10.1038/leu.2015.247 · Cited by 864 · see citing works
Shah, B. D., Ghobadi, A., Oluwole, O. O., Logan, A. C., Boissel, N., Cassaday, R. D., Leguay, T., Bishop, M. R., Topp, M. S., Tzachanis, D., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01222-8 · Cited by 837 · see citing works
Kamdar, M. K., Solomon, S. R., Arnason, J. E., Johnston, P. B., Glaß, B., Bachanová, V., Ibrahimi, S., Mielke, S., Mutsaers, P. G. N. J., Hernandez‐Ilizaliturri, F. J., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 809 · see citing works
Global Manufacturing of CAR T Cell Therapy
Levine, B. L., Miskin, J., Wonnacott, K., & Keir, C. (2017) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2016.12.006 · Cited by 765 · see citing works
Till, B. G., Jensen, M. C., Wang, J., Chen, E., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A. A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 721 · see citing works
Jacobson, C. A., Chávez, J. C., Sehgal, A. R., William, B. M., Munoz, J. L., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 674 · see citing works
Clinical manufacturing of CAR T cells: foundation of a promising therapy
Wang, X., & Rivière, I. (2016) · Molecular Therapy - Oncolytics · doi:10.1038/mto.2016.15 · Cited by 637 · see citing works
Spiegel, J. Y., Patel, S., Muffly, L. S., Hossain, N. M., Oak, J. S., Baird, J. H., Frank, M. J., Shiraz, P., Sahaf, B., Craig, J. K., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01436-0 · Cited by 624 · see citing works
Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results
Qi, C., Gong, J., Li, J., Liu, D., Qin, Y., Ge, S., Zhang, M., Peng, Z., Zhou, J., Cao, Y., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01800-8 · Cited by 604 · see citing works
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M. J., Dreyling, M. H., Martínez‐López, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L. L., Chávez, J. C., Bachy, E., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 562 · see citing works
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1081-3 · Cited by 468 · see citing works
Benjamin, R., Graham, C., Yallop, D., Jozwik, A., Mirci‐Danicar, O., Lucchini, G., Pinner, D., Jain, N., Kantarjian, H., Boissel, N., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)32334-5 · Cited by 376 · see citing works
Scalable Manufacturing of CAR T Cells for Cancer Immunotherapy
Abou-el-Enein, M., Elsallab, M., Feldman, S. A., Fesnak, A. D., Heslop, H. E., Marks, P., Till, B. G., Bauer, G., & Savoldo, B. (2021) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-21-0084 · Cited by 321 · see citing works
Brudno, J. N., Lam, N., Vanasse, D., Shen, Y.-W., Rose, J. J., Rossi, J. M., Xue, A. X., Bot, A. I., Scholler, N., Mikkilineni, L., et al. (2020) · Nature Medicine · doi:10.1038/s41591-019-0737-3 · Cited by 309 · see citing works
Immunogenicity of CAR T cells in cancer therapy
Wagner, D. L., Fritsche, E., Pulsipher, M. A., Ahmed, N. M., Hamieh, M., Hegde, M. G., Ruella, M., Savoldo, B., Shah, N. N., Turtle, C. J., et al. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00476-2 · Cited by 307 · see citing works
Micklethwaite, K. P., Gowrishankar, K., Gloss, B. S., Li, Z., Street, J. A., Moezzi, L., Mach, M. A., Sutrave, G., Clancy, L. E., Bishop, D. C., et al. (2021) · Blood · doi:10.1182/blood.2021010858 · Cited by 226 · see citing works
Financial toxicity and implications for cancer care in the era of molecular and immune therapies
Tran, G. N., & Zafar, S. Y. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.03.28 · Cited by 222 · see citing works
Li, Y., & Kurlander, R. J. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-104 · Cited by 209 · see citing works
Towards a commercial process for the manufacture of genetically modified T cells for therapy
Kaiser, A., Assenmacher, M., Schröder, B., Meyer, M., Orentas, R. J., Bethke, U., & Dropulić, B. (2015) · Cancer Gene Therapy · doi:10.1038/cgt.2014.78 · Cited by 202 · see citing works
Sleeping Beauty–engineered CAR T cells achieve antileukemic activity without severe toxicities
Magnani, C. F., Gaipa, G., Lussana, F., Belotti, D., Gritti, G., Napolitano, S., Matera, G., Cabiati, B., Buracchi, C., Borleri, G., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138473 · Cited by 193 · see citing works
Ortiz‐Maldonado, V., Rives, S., Castellà, M., Alonso‐Saladrigues, A., Benítez‐Ribas, D., Caballero‐Baños, M., Baumann, T., Cid, J., García‐Rey, E., Llanos, C., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.027 · Cited by 167 · see citing works
Autologous lymphapheresis for the production of chimeric antigen receptor T cells
Allen, E. S., Stroncek, D. F., Ren, J., Eder, A. F., West, K. A., Fry, T. J., Lee, D. W., Mackall, C. L., & Conry‐Cantilena, C. (2017) · Transfusion · doi:10.1111/trf.14003 · Cited by 158 · see citing works
Comparative analysis of assays to measure CAR T cell-mediated cytotoxicity
Kiesgen, S., Messinger, J. C., Chintala, N. K., Tano, Z., & Adusumilli, P. S. (2021) · Nature Protocols · doi:10.1038/s41596-020-00467-0 · Cited by 138 · see citing works
The market for chimeric antigen receptor T cell therapies
Yip, A., & Webster, R. M. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.266 · Cited by 137 · see citing works
Siddiqi, T., Soumerai, J. D., Dorritie, K. A., Stephens, D. M., Riedell, P. A., Arnason, J. E., Kipps, T. J., Gillenwater, H. H., Gong, L., Yang, L., et al. (2021) · Blood · doi:10.1182/blood.2021011895 · Cited by 123 · see citing works
Zhu, F., Shah, N., Xu, H., Schneider, D., Orentas, R., Dropulic, B., Hari, P., & Keever-Taylor, C. A. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2017.09.005 · Cited by 120 · see citing works
Estimating a cost-effectiveness threshold for health care decision-making in South Africa
Edoka, I., & Stacey, N. (2019) · Health Policy and Planning · doi:10.1093/heapol/czz152 · Cited by 119 · see citing works
Sherba, J. J., Hogquist, S., Lin, H., Shan, J. W., Shreiber, D. I., & Zahn, J. D. (2020) · Scientific Reports · doi:10.1038/s41598-020-59790-x · Cited by 117 · see citing works
Addressing the Value of Gene Therapy and Enhancing Patient Access to Transformative Treatments
Salzman, R., Cook, F., Hunt, T. D., Malech, H. L., Reilly, P. R., Foss-Campbell, B., & Barrett, D. M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.10.017 · Cited by 115 · see citing works
Automated manufacture of autologous CD19 CAR-T cells for treatment of non-hodgkin lymphoma
Jackson, Z., Roe, A., Sharma, A. A., Lopes, F. B. T. P., Talla, A., Kleinsorge-Block, S., Zamborsky, K., Schiavone, J., Manjappa, S., Schauner, R., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01941 · Cited by 102 · see citing works
Palani, H. K., Arunachalam, A. K., Yasar, M., Venkatraman, A., Kulkarni, U., Lionel, S. A., Selvarajan, S., Korula, A., Abraham, A., George, B., et al. (2023) · Bone Marrow Transplantation · doi:10.1038/s41409-022-01866-5 · Cited by 89 · see citing works
Maschan, M., Caimi, P. F., Reese-Koc, J., Sanchez, G. P., Sharma, A. A., Molostova, O., Shelikhova, L., Pershin, D., Stepanov, A., Muzalevskii, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27312-6 · Cited by 88 · see citing works
Abou-El-Enein, M., Römhild, A., Kaiser, D., Beier, C., Bauer, G., Volk, H.-D., & Reinke, P. (2013) · Cytotherapy · doi:10.1016/j.jcyt.2012.09.006 · Cited by 86 · see citing works
Baird, J. H., Frank, M. J., Craig, J. K., Patel, S., Spiegel, J. Y., Sahaf, B., Oak, J. S., Younes, S. F., Ozawa, M. G., Yang, E., et al. (2020) · Blood · doi:10.1182/blood.2020009432 · Cited by 79 · see citing works
CAR-T cell therapies from the transfusion medicine perspective
Fesnak, A., Lin, C., Siegel, D., & Maus, M. V. (2016) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2016.03.001 · Cited by 77 · see citing works
Gee, A. P. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.01.002 · Cited by 75 · see citing works
Large-Scale Production Means for the Manufacturing of Lentiviral Vectors
Schweizer, M., & Merten, O.-W. (2010) · Current Gene Therapy · doi:10.2174/156652310793797748 · Cited by 69 · see citing works
CAR T-cell therapies in China: rapid evolution and a bright future
Hu, Y., Feng, J., Gu, T., Wang, L., Wang, Y., Zhou, L., Hong, R., Yin, E. T. S., Zhang, M., Lu, P., et al. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00291-5 · Cited by 54 · see citing works
Priesner, C., Aleksandrova, K., Esser, R., Mockel-Tenbrinck, N., Leise, J., Drechsel, K., Marburger, M., Quaiser, A., Goudeva, L., Arseniev, L., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.091 · Cited by 52 · see citing works
Advances in automated cell washing and concentration
Li, A., Kusuma, G. D., Driscoll, D., Smith, N., Wall, D. M., Levine, B. L., James, D., & Lim, R. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2021.04.003 · Cited by 50 · see citing works
Recent Advances in the Development of Bioreactors for Manufacturing of Adoptive Cell Immunotherapies
Ganeeva, I., Zmievskaya, E., Valiullina, A., Kudriaeva, A. A., Рифкатовна, М. Р., Rybalov, A. A., & Bulatov, E. (2022) · Bioengineering · doi:10.3390/bioengineering9120808 · Cited by 47 · see citing works
Rapid Lentiviral Vector Producer Cell Line Generation Using a Single DNA Construct
Chen, Y. H., Pallant, C., Sampson, C. J., Boiti, A., Johnson, S. N., Brazauskas, P., Hardwicke, P. I., Marongiu, M. E., Marinova, V. M., Carmo, M., et al. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.011 · Cited by 43 · see citing works
Lam, C., Meinert, E., Yang, A., & Cui, Z. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2020.08.007 · Cited by 42 · see citing works
Kedmi, M., Shouval, R., Fried, S., Bomze, D., Fein, J. A., Cohen, Z., Danilesko, I., Shem‐Tov, N., Yerushalmi, R., Jacoby, E., et al. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.02.017 · Cited by 39 · see citing works
Development of CAR-T cell therapy for B-ALL using a point-of-care approach
Abdo, L. D. M., Barros, L. R. C., Viegas, M. S., Marques, L. V. C., Ferreira, P. D. S., Chicaybam, L., & Bonamino, M. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1752592 · Cited by 38 · see citing works
Lentiviral Vector Production from a Stable Packaging Cell Line Using a Packed Bed Bioreactor
Powers, A. D., Drury, J. E., Hoehamer, C. F., Lockey, T. D., & Meagher, M. M. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2020.08.010 · Cited by 32 · see citing works
Kekre, N. K., Hay, K. A., Webb, J. R., Mallick, R., Balasundaram, M., Sigrist, M. K., Clement, A.-M., Nielsen, J. S., Quizi, J. L., Yung, E., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1074740 · Cited by 31 · see citing works
Lutfi, F. U., Holtzman, N. G., Kansagra, A. J., Ali, M. K. M., Bukhari, A. A., Yan, J., Samanta, S., Gottlieb, D., Kim, D. W., Matsumoto, L. R., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17738 · Cited by 30 · see citing works
Developing an Automated Robotic Factory for Novel Stem Cell Therapy Production
Rafiq, Q. A., Twomey, K., Kulik, M. J., Leschke, C., O’Dea, J., Callens, S., Gentili, C., Barry, F., & Murphy, M. J. (2016) · Regenerative Medicine · doi:10.2217/rme-2016-0040 · Cited by 30 · see citing works
de Landazuri, I. O., Egri, N., Muñoz‐Sánchez, G., Ortiz‐Maldonado, V., Bolaño, V., Guijarro, C., Pascal, M., & Juan, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.573179 · Cited by 19 · see citing works
Primus, C., Rocha, M. N. D., Warda, W., Roussel, X., Haderbache, R., Seffar, E., Trad, R., Bouquet, L., Goncalves, M., Bosdure, L., et al. (2023) · Current Research in Translational Medicine · doi:10.1016/j.retram.2023.103385 · Cited by 19 · see citing works
Syed, F., El Fakih, R., Alahmari, A. D., Ali, A. S. O., & Aljurf, M. (2022) · Hematology/Oncology and Stem Cell Therapy · doi:10.56875/2589-0646.1048 · Cited by 18 · see citing works
459. Evaluation of Miltenyi ExpAct and TransAct CD3/28 Beads for CAR-T Cell Manufacturing
Wang, X., Qu, J., Stefanski, J., Bórquez-Ojeda, O., Hack, A., He, Q., Wasielewska, T., Du, F., Sadelain, M., & Rivière, I. (2016) · Molecular Therapy · doi:10.1016/s1525-0016(16)33268-3 · Cited by 14 · see citing works
Point-of-care CAR T-cell therapy as salvage strategy for out-of-specification tisagenlecleucel
Fried, S., Shouval, R., Varda‐Bloom, N., Besser, M. J., Yerushalmi, R., Shem‐Tov, N., Danylesko, I., Jacoby, E., Teihman, S., Itzhaki, O., et al. (2022) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2022.2123232 · Cited by 13 · see citing works
Standards efforts and landscape for rapid microbial testing methodologies in regenerative medicine
Lin-Gibson, S., Lin, N. J., Jackson, S., Viswanathan, S., Zylberberg, C., Wolfrum, J., Basu, S., Roy, K., Marshall, D., McFarland, R., et al. (2021) · Cytotherapy · doi:10.1016/j.jcyt.2020.07.006 · Cited by 12 · see citing works
Ramakrishnan, S., Kumar, J., Datta, S. S., Radhakrishnan, V. S., Nair, R., & Chandy, M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1062296 · Cited by 10 · see citing works
Cut-price CAR-T cell therapies top India’s biotech agenda
Jayaraman, K. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0346-1 · Cited by 8 · see citing works
Vasu, S., Alinari, L., Szuminski, N., Schneider, D., Denlinger, N., Chan, W. K., Parris, K., Sharma, N., Bradbury, H., Daneault, B., et al. (2022) · Blood · doi:10.1182/blood-2022-167340 · Cited by 6 · see citing works
Self-citationAnguille, S., Kuipers, I., Saevels, K., Beguin, Y. P., van Muyden, A. D. D., Jacques, C. J., & Kersten, M. J. (2022) · Blood · doi:10.1182/blood-2022-163830 · Cited by 6 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Cost-effective strategies for CAR-T cell therapy manufacturing
Abdo, L., Batista-Silva, L., & Bonamino, M. (2025) · Molecular therapy. Oncology · doi:10.1016/j.omton.2025.200980 · Cited by 58 · see citing works
Agarwal, T., Onesto, V., Banerjee, D., Guo, S., Polini, A., Vogt, C. D., Viswanath, A., Esworthy, T. J., Cui, H., O'Donnell, A., et al. (2025) · Biofabrication · doi:10.1088/1758-5090/ade47a · Cited by 64 · see citing works
Alidadi, M., Barzgar, H., Zaman, M., Paevskaya, O. A., Metanat, Y., Khodabandehloo, E., & Moradi, V. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1491282 · Cited by 33 · see citing works
The Potential Use of Digital Twin Technology for Advancing CAR-T Cell Therapy
Aghamiri, S., & Amin, R. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47050321 · Cited by 27 · see citing works
Gupta, D., & Shaz, B. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06400-x · Cited by 32 · see citing works
Wang, Z., & Kelley, S. O. (2025) · Nature Biomedical Engineering · doi:10.1038/s41551-024-01315-2 · Cited by 32 · see citing works
Global Oncology: Tackling Disparities and Promoting Innovations in Low- and Middle-Income Countries
Barragán-Carrillo, R., Asirwa, F. C., Dienstmann, R., Pendhakar, D., & Ruíz‐García, E. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473930 · Cited by 26 · see citing works
Chiu, Y.-S., Wang, K.-L., & Wu, K.-L. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1644318 · Cited by 17 · see citing works
“…fi cantlyreduces time between manufacturing and patient treatment. harvesting, and fi nal formulation within a single sterile unit, offering a streamlined approach to manufacturing ATMPs near the point of care (Harrison et al., 2017; Shah et al., 2023).”
Luanpitpong, S., Klaihmon, P., Janan, M., Kungwankiattichai, S., Owattanapanich, W., Kunacheewa, C., Chanthateyanonth, S., Donsakul, N., U-pratya, Y., Warindpong, T., et al. (2024) · Molecular Therapy: Oncology · doi:10.1016/j.omton.2024.200889 · Cited by 17 · see citing works
Lemgart, V. T., Sawyer, A. J., Kuhlman, W. A., Griset, A. P., Ali, M. M., Caron, A., Shah, D., Le, T. T., Strauss, L., Jiao, J., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.020 · Cited by 17 · see citing works
Marton, C., Clémenceau, B., Dachy, G., Demerle, C., Derenne, S., Ferrand, C., Giverne, C., Latouche, J.-B., Lemée, L., Martinet, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02637-8 · Cited by 16 · see citing works
Innovative gene engineering strategies to address tumor antigen escape in cell therapy
Chen, Y., Niu, S., Li, Y.-R., & Yang, L. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-07259-8 · Cited by 17 · see citing works
Rapid manufacturing of CAR-T therapy: strategies and impact
Chen, S., & Liu, D. (2024) · Trends in biotechnology · doi:10.1016/j.tibtech.2024.09.013 · Cited by 15 · see citing works
von der Leyen, H. E., Delgado, J., Mazouz, C., Schmitt, M. W., & Caplan, V. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1591751 · Cited by 11 · see citing works
Contemporary Approaches to Immunotherapy of Solid Tumors
Kuznetsova, A. V., Glukhova, K. А., Попова, О. П., Петрович, Б. И., & Aa, I. (2024) · Cancers · doi:10.3390/cancers16122270 · Cited by 11 · see citing works
Caël, B., Bôle‐Richard, E., Garnache‐Ottou, F., & Aubin, F. (2024) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2024.12.1066 · Cited by 11 · see citing works
Distributed Biomanufacturing Facilities of the Future
Kadolkar, R., Kumar, V., Thole, A., Patel, D., Ujjain, S. K., George, I., Wei, Y., Prajapati, T., Zafar, S., Faris, N., et al. (2025) · Biotechnology and Bioengineering · doi:10.1002/bit.70039 · Cited by 8 · see citing works
Kok, N., Dekkers, Z., Loos, A., Bos, T., van den Broek, P., Post, I., Niessen, B., Spanholtz, J., Huppert, V., & Raimo, M. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1586912 · Cited by 7 · see citing works
Nanobody CAR-T cells in cancer: From molecular design to clinical translation
Eisa, A. R., Razavi, F. T., Hoseinzadeh, A., Haghmorad, D., & Baharlou, R. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118819 · Cited by 7 · see citing works
Szarzynski, A., Oliver Spadiut, A., Reisbeck, M., Jobst, G., Paterson, R. L., Kamenskaya, A., Gateau, E., Lesch, H. P., Henry, L., & Kozma, B. (2025) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2025.1563878 · Cited by 6 · see citing works
Process Systems Engineering in Precision Medicine: Opportunities in Autologous CAR‐T Therapy
Bequette, B. W. (2026) · Engineering in Life Sciences · doi:10.1002/elsc.70067 · Cited by 6 · see citing works
Optimizing bridging radiotherapy prior to CAR-T cell therapy: An evidence-based approach
Loap, P., Sarkozy, C., Dendale, R., & Kirova, Y. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105181 · Cited by 6 · see citing works
Boyer, O., Bensoussan, D., Bonig, H. B., Chabannon, C., Clemenceau, B., Cuffel, A., Dachy, G., Vos, J. D., Derenne, S., Diana, J., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-024-02504-y · Cited by 6 · see citing works
Huang, S., Lin, Y., Pan, C., Chen, Y., Shie, M., Chen, C., Kan, K., Chen, Y.-W., Liu, M., Wu, C., et al. (2026) · Advanced Science · doi:10.1002/advs.202519440 · Cited by 5 · see citing works
The New Wave of Gene and Cell Therapies Across Diseases
Rieske, A., Grot, D., Tręda, C., Włodarczyk, A., Stoczyńska-Fidelus, E., Jaskólska, M., & Rieske, P. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15051799 · Cited by 4 · see citing works
Advanced Therapy Medicinal Products: Availability, Access and Expenditure in Italy
Cervo, P. R. D. V., Alessi, E., Lastella, M., Greca, A. L., & Trotta, F. (2024) · BioDrugs · doi:10.1007/s40259-024-00683-0 · Cited by 4 · see citing works
Chang, Y. H., Fujimori, Y., Chen, C., Urabe, M., Karaki, T., Izumi, Y., Kaneko, K., & Mochiki, K. (2025) · Therapeutic Innovation & Regulatory Science · doi:10.1007/s43441-025-00808-9 · Cited by 4 · see citing works
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists
Mushtaq, A. H., Cheema, A. Y., Ali, H. M., Shatnawi, Y., Ashruf, O. S., Ahmad, E. N., Lytvynova, O., Munir, M., Asif, M. A., Ahmad, M., et al. (2025) · Blood Reviews · doi:10.1016/j.blre.2025.101339 · Cited by 4 · see citing works
Strategies to Enhance Stability of Cryopreservation Processes for Cell-Based Products
Uno, Y., Hayashi, Y., Sugiyama, H., Okuda, J., Nakamura, T., & Kino‐oka, M. (2025) · Biotechnology Advances · doi:10.1016/j.biotechadv.2025.108763 · Cited by 3 · see citing works
Justiz-Vaillant, A. A., Soodeen, S., Gopaul, D. A., Arozarena-Fundora, R., & Akpaka, P. E. (2026) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2026.1931159 · Cited by 3 · see citing works
Germain, L., & Winn, L. M. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104453 · Cited by 2 · see citing works
The Coming of Age of Gene Therapy for the Treatment of Human Diseases: A Regulatory Perspective
Rodríguez, L., de Felipe, P., Martín, R., Martínez, J., Ordóñez, D., Rojo, S., Martínez, J. F., Rincón, E., Cejalvo, T., Izquierdo, I., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251372047 · Cited by 2 · see citing works
Broadening CAR-T access: lessons from real-world implementation of talicabtagene autoleucel in India
Purwar, A., Jain, H., & Kumar, S. (2025) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2025.100026 · Cited by 2 · see citing works
Cheung, K.-W., Kairi, F., Teo, D. B. L., Sin, W., Luah, Y. H., Chen, Y., Lim, F., Lee, Y. H., & Birnbaum, M. E. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.05.002 · Cited by 1 · see citing works
Outcomes following CD22 CAR T-cells in B-ALL: a tale of two manufacturing strategies
Dreyzin, A., Kramer, A. M., Yates, B., Wang, H., Sahaf, B., Yuan, C. M., Klysz, D. D., Tunuguntla, R. H., Ehlinger, Z. J., Reitberg, S., et al. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.09.013 · Cited by 1 · see citing works
Mukherjee, A. M. (2025) · Proceedings of the Indian National Science Academy · doi:10.1007/s43538-025-00572-2 · Cited by 1 · see citing works
El impacto de la terapia celular CAR-T en el manejo actual del cáncer y su panorama en Colombia
García-Robledo, J. E., Wills, B., Salguero, G., Polo, V. A., Baena, J. C., & Martínez‐Cordero, H. (2025) · Revista Colombiana de Cancerología · doi:10.35509/01239015.1156 · Cited by 1 · see citing works
Regulatory landscape for CAR-T therapy development in the Brazilian context
Mesquita, F. P., Maia, M. S., Souza, P. F. N., Carvalho, L. E. M., Carlos, L. M. D. B., & DUARTE, F. B. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2617956 · Cited by 1 · see citing works
Elsemary, M. T., Maritz, M. F., Smith, L. E., Warkiani, M. E., & Thierry, B. (2026) · Medical Oncology · doi:10.1007/s12032-026-03276-9 · Cited by 1 · see citing works
Pham, D. L., Kalluri, M., Weaver, C., Hsu, A., Gillette, A. A., Zhao, W., Kearl, T. J., Hematti, P., Shah, N. N., & Skala, M. C. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201704 · Cited by 1 · see citing works
A critical review of microfluidic electroporation for therapeutic cell engineering
Hoyle, M., Arroyo, J. P., Davalos, R. V., & Sarkar, A. (2026) · Cell Reports Physical Science · doi:10.1016/j.xcrp.2026.103142 · Cited by 1 · see citing works
Overcoming five main challenges to targeting hematologic malignancies
Thakkar, M., Hanley, P. J., Bersenev, A., & Steffin, D. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102776 · Cited by 1 · see citing works
Decentralized CAR-T manufacturing: highlighting regulatory pathways in the United States and abroad
Shah, N. N., Urbano-Ispizúa, Á., Annunzio, K., López, L. P., Olesti, E., Bassett, E., & Kekre, N. K. (2026) · Blood Immunology & Cellular Therapy · doi:10.1016/j.bict.2026.100053 · Cited by 1 · see citing works
Li, H., Yan, J., Liu, Y., Tao, X., Guo, K., & Zhang, J. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1797270 · Cited by 1 · see citing works
Nahum, S., Doshi, D., Kosnik, C., Jeffries, E., Nishida, K. S., Caplan, V., & von der Leyen, H. E. (2026) · Regenerative Therapy · doi:10.1016/j.reth.2026.101112 · Cited by 1 · see citing works
In vivo CAR-T for the treatment of autoimmune diseases: Current progress and future directions
Zhao, Y., Liu, Y., Peng, X., Ma, X., & Yang, Q. (2026) · Genes & Diseases · doi:10.1016/j.gendis.2026.102245 · Cited by 1 · see citing works
Griebling, D., Scheiwe, A. R., Kuhlen, R., Zech, C., Muller, P., Rische, C., Längst, V., Wegener, C., Schmidt, L., Bothwell, P., et al. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102939 · Cited by 1 · see citing works
Halahleh, K., Abu-Khader, A., Abu‐Jazar, H., Makoseh, M., Da'Na, W. K., Alfar, R., Qabajah, T., Al-Sharairy, M., Najjar, R., Taqash, A., et al. (2026) · JCO Global Oncology · doi:10.1200/go-25-00648 · Cited by 1 · see citing works
The future of TCR-Treg therapies is renewables
Peh, C. R., Nguyen‐Dumont, T., Ting, Y. T., & Ooi, J. D. (2026) · Autoimmunity Reviews · doi:10.1016/j.autrev.2026.104139 · Cited by 1 · see citing works
Nasiri, A. M., Fakih, R. O. E., Chabannon, C., Garderet, L., Kuball, J. H. E., Bazarbachi, A. A., Sureda, A. M., Lima, M. J. G. D., Abid, M. B., Syed, F., et al. (2026) · Bone Marrow Transplantation · doi:10.1038/s41409-026-03044-3 · Cited by 1 · see citing works
Balanean, A., Baird, S., Dulka, B. N., Jennings‐Zhang, L., Bone, R. N., Jeune‐Smith, Y., Feinberg, B. A., & Baljević, M. (2024) · eJHaem · doi:10.1002/jha2.1047 · Cited by 1 · see citing works
RNA‐Based and Gene Therapy Approaches in Cancer Treatment
Rai, P., Pandey, R. K., Mehrotra, S., & Singh, A. (2026) · doi:10.1002/9781394376490.ch14 · Cited by 1 · see citing works
Jain, H. (2024) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_582_24
CAR-T Cell Therapy: A Revolutionary Approach to Targeting and Treating Cancer
Kumar, V., Kumar, D., Verma, M., Pruthi, H., Dhiman, T., Khatri, N., Garg, V., Kakkar, S., & Kumar, A. (2025) · Clinical Cancer Drugs · doi:10.2174/012212697x366863250331152051
Mulvey, E. C., Shafrin, J. T., Than, K., Muthukrishnan, S., Mutebi, A., Chhibber, A., Wang, A., Alshreef, A., Harb, D. E., Gonzalez, V., et al. (2025) · Future Oncology · doi:10.1080/14796694.2025.2572784
Chartral, U., Galaine, J., Giverne, C., Auxenfans, C., Reppel, L., Marton, C., Thiant, S., Clemenceau, B., Derenne, S., Sabatier, F., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02756-2
Car-T Cell Therapy: A Paradigm Shift in Cancer Treatment
Hajare, P. K., Lokhande, R., Game, N., & Patki, S. P. (2026) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v16i3.7599
Plying potency assays for immunotherapy of solid tumors
Burns, J. S., Gjeta, R., Lesný, P., & Vives, J. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1770222
Alsubki, R. A. (2026) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2026.105304
Development of Next-generation CAR-T Cell Therapy to Overcome Solid Tumors
Kim, Y. U., Kim, Y., Lee, K.-S., Bang, J., Seo, G., Hong, S., & Lim, K. S. (2026) · KSBB Journal · doi:10.7841/ksbbj.2026.41.1.16
Role of cytokines in cancer immunology
Madan, E., Bissa, B., Goel, A., Khan, M. S., Chandra, N., Jain, K., Tiwari, A., Soni, N., & Mandlik, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-41551-7.00021-7
CAR-T cells and cancer nanovaccines: Comparative insights into advances and translational challenges
Zaccariotto, G. D. C., & Zucolotto, V. (2026) · Biotechnology Advances · doi:10.1016/j.biotechadv.2026.108942
Chimeric antigen receptor-based immunotherapies in cancer treatment: An Indian perspective
Kulkarni, A., Kulkarni, A., & Sharma, N. K. (2026) · Indian Journal of Physiology and Pharmacology · doi:10.25259/ijpp_541_2025
Impact of cryopreservation on PBMC-derived CAR-T cell manufacturing outcomes: a systematic review
Al-Wreidat, R. A., Alshwayyat, S., Maharma, L. A., & Al-Hussaini, M. A. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1876909
Andreotti, I. A. D. A., Griep, G., Patino-Narino, E., Batista-Silva, L. R., Gongora-Rubio, M., Bonamino, M., & Balbino, T. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08388-4 · Cited by 1 · see citing works
Atsumi, Y., Niwa, A., Kitagawa, Y., Kumaki, T., Yagyu, S., Nakazawa, Y., & Saito, M. K. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.102976
In vivo CAR-T therapy: The shift from ex vivo culturing to direct in situ immune reprogramming
Gopalakrishnan, J., Rathod, B., & Puri, S. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.117255
Advances in the development and delivery of nucleic acid-based therapeutics
Kurczewski, E., Mansurov, A., Sachar, C., & Guler, M. O. (2026) · Biomaterials Science · doi:10.1039/d6bm00738d
Cabrera-Salcedo, S. C., Parra‐Lara, L. G., Fernandes-Pineda, M., Toro-Pedroza, A., Hincapie, J. S. V., Ríos-Serna, L. J., Loukanov, A. R., Ortiz‐Guzman, J., García-Robledo, J. E., Cañas, C. A., et al. (2026) · Frontiers in Public Health · doi:10.3389/fpubh.2026.1875553
van der Walle, C. F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45791-3.00005-6
Phase 1 evaluation of APN401, an autologous CBL-B-silenced PBMC therapy, in advanced solid tumors
Dohnal, A. M., Worel, N., Bogenrieder, T., Fuereder, T., Burian, M., Wolf, D., Prager, G. W., Greil, R., Peterbauer-Scherb, A., Schrenk, B., et al. (2026) · Molecular Therapy Oncology · doi:10.1016/j.omton.2026.201357
Chan, W. W., Lim, E. Z. Y., & Choudhury, D. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1861621
Shaz, B. H., Gupta, D., Dinh, A., Schwartz, J., Thibodeau, S., & Fontaine, M. J. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103034
Stathoulis, A., Fernandez, D., Doig, C., & Fiorenza, S. (2026) · Biologicals · doi:10.1016/j.biologicals.2026.101918
Future directions in nanomedicine and microfluidics
Tafazzoli, K., Tafazoli, M. H., & Hataminia, F. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-45538-4.00015-7
The Commercial Viability of Cell Therapy: We Cannot Continue to Accept the Status Quo
Heathman, T. R. J., & Trinkle, K. (2026) · Cytotherapy · doi:10.1016/j.jcyt.2026.103039
- Authors
- Shah, M., Krull, A., Odonnell, L., de Lima, M. J., & Bezerra, E.
- Affiliations
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Corresponding author
- Bezerra, Evandro
- Venue
- Frontiers in Transplantation
- Publisher
- Frontiers Media SA
- Published
- 2023-09-05
- Volume
- 2
- Pages
- 1238535-1238535
- ISSN
- 2813-2440 (ISSN-L)
- PMC
- PMC11235344
- OpenAlex
- W4386442016
- Cited by
- 77
- References
- 75
- Citations by year
- 2026: 41 · 2025: 28 · 2024: 8
- FWCI
- 2.50
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Frontiers in Transplantation (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, distributed manufacturing, point-of-care manufacturing, autologous cell therapy, in-house production, production costs, quality control, current good manufacturing practice, patient access, relapsed/refractory B-cell malignancies, plasma cell malignancy, cell therapy manufacturing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
